Coalition For Pulmonary Fibrosis Responds To News Of Further Review Of Pirfenidone By FDA
Hospitals Falling Short on Heart Patients’ Follow-Up Care
Read more on HealthDay via Yahoo! News
TUESDAY, May 4 (HealthDay News) — A quick follow-up visit by a medical professional to a heart failure patient discharged from the hospital reduces the chance that the patient will wind up back in the hospital, but that preventive measure is more often ignored than observed, a new study finds.GeneNews Announces Board and Management Changes
Read more on Marketwire via Yahoo! Finance
TORONTO, CANADA–(Marketwire – 05/04/10) – GeneNews Limited (TSX: GEN – News ), an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management, today announced Board and management changes following the Company’s Annual and Special Meeting of Shareholders held on May 3, 2010 in Toronto. Appointment of Ms …Midwest Microcurrent Offers Unique Pet Paralysis Treatment
Read more on dBusinessNews.com
Seattle – Union, Missouri, May 5th, 2010 – Midwest Microcurrent, a company that specializes in pet joint pain and anxiety alleviation, announced today their unique ability to treat animals using Alpha-Stim® Microcurrent technology.IP Update
Read more on GenomeWeb News
The patent, its abstract states, claims “compounds, compositions, and methods … for modulating the RNAi pathway.Coalition For Pulmonary Fibrosis Responds To News Of Further Review Of Pirfenidone By FDA
Read more on Medical News Today
The Coalition for Pulmonary Fibrosis (CPF), representing tens of thousands of patients, is responding to the news that the FDA chose to ask for further study of Pirfenidone, which will delay potential approval of the first drug in the treatment of Pulmonary Fibrosis (PF), a lethal lung disease that is irreversible, progressive and deadly in an average of three years. On March 9, 2010, an FDA …
Leave a Comment